Dokument: Carrageenan and insulin resistance in humans: a randomised double-blind cross-over trial
| Titel: | Carrageenan and insulin resistance in humans: a randomised double-blind cross-over trial | |||||||
| URL für Lesezeichen: | https://docserv.uni-duesseldorf.de/servlets/DocumentServlet?id=68318 | |||||||
| URN (NBN): | urn:nbn:de:hbz:061-20250128-110549-0 | |||||||
| Kollektion: | Publikationen | |||||||
| Sprache: | Englisch | |||||||
| Dokumententyp: | Wissenschaftliche Texte » Artikel, Aufsatz | |||||||
| Medientyp: | Text | |||||||
| Autoren: | Wagner, Robert [Autor] Buettner, Janine [Autor] Heni, Martin [Autor] Fritsche, Louise [Autor] Kullmann, Stephanie [Autor] Wagmüller, Moritz [Autor] Peter, Andreas [Autor] Preissl, Hubert [Autor] Machann, Jürgen [Autor] Jumpertz von Schwartzenberg, Reiner [Autor] | |||||||
| Dateien: |
| |||||||
| Stichwörter: | Gut microbiome, Type 2 diabetes, Carrageenan, Emulsifiers, Intestinal permeability, Insulin sensitivity | |||||||
| Beschreibung: | Background
The potential impact of specific food additives, common in Western diets, on the risk of developing type 2 diabetes is not well understood. This study focuses on carrageenan, a widely used food additive known to induce insulin resistance and gut inflammation in animal models, and its effects on human health. Methods In a randomised, double-blind, placebo-controlled, cross-over trial conducted at a university hospital metabolic study centre, 20 males (age 27.4 ± 4.3 years, BMI 24.5 ± 2.5 kg/m2) participated. The intervention involved oral intake of carrageenan (250 mg) or placebo in the morning and in the evening and each intervention lasted 2 weeks. The primary outcome measured was insulin sensitivity (using oral glucose tolerance test [OGTT] and hyperinsulinaemic-euglycaemic clamp). Additional end-points included whole body and hepatic insulin sensitivity, MRI-measured brain inflammation and insulin resistance, intestinal permeability (via lactulose-mannitol test and plasma zonulin levels), and gut microbiome composition. Immune-cell activation and pro-inflammatory cytokine release from peripheral blood mononuclear cells were measured. Results Overall insulin sensitivity did not show significant differences between the treatments. However, interactions between BMI and treatment were observed (OGTT-based insulin sensitivity index: p=0.04, fasting insulin resistance: p=0.01, hepatic insulin sensitivity index: p=0.04). In overweight participants, carrageenan exposure resulted in lower whole body and hepatic insulin sensitivity, a trend towards increased brain inflammation, and elevated C-reactive protein (CRP) and IL-6 levels compared to placebo. Additionally, carrageenan was associated with increased intestinal permeability. In vitro natural killer (NK-)cell activation and increased pro-inflammatory cytokine release were found after carrageenan exposure in the participant’s peripheral blood mononuclear cells. Conclusions These findings suggest that carrageenan, a common food additive, may contribute to insulin resistance and subclinical inflammation in overweight individuals through pro-inflammatory mechanisms in the gut. Further investigation into the long-term health impacts of carrageenan and other food additives is warranted. | |||||||
| Rechtliche Vermerke: | Originalveröffentlichung:
Wagner, R., Buettner, J., Heni, M., Fritsche, L., Kullmann, S., Wagmüller, M., Peter, A., Preissl, H., Machann, J., Jumpertz von Schwartzenberg, R., Birkenfeld, A. L., Pape, U.-F., van Hall, G., Plomgaard, P., Häring, H.-U., Fritsche, A., Thompson, K. N., Klein, R., & Stefan, N. (2024). Carrageenan and insulin resistance in humans: a randomised double-blind cross-over trial. BMC Medicine, 22, Article 558. https://doi.org/10.1186/s12916-024-03771-8 | |||||||
| Lizenz: |  Dieses Werk ist lizenziert unter einer Creative Commons Namensnennung 4.0 International Lizenz | |||||||
| Fachbereich / Einrichtung: | Medizinische Fakultät | |||||||
| Dokument erstellt am: | 28.01.2025 | |||||||
| Dateien geändert am: | 28.01.2025 |
